Thermo Fisher Scientific (NYSE:TMO) announced today that it entered into a definitive agreement to acquire The Binding Site Group. The Binding Site develops specialty diagnostic assays and instruments. It designs its technology to improve the diagnosis and management of blood cancers and immune system disorders. The Binding Site’s Freelite offering aids in multiple myeloma diagnosis […]